Literature DB >> 33001476

The progression of salt-wasting and the body weight change during the first 2 weeks of life in classical 21-hydroxylase deficiency patients.

Maki Gau1, Kaoru Konishi2, Kei Takasawa1, Ryuichi Nakagawa1, Atsumi Tsuji-Hosokawa1, Atsuko Hashimoto2, Akito Sutani1, Toshihiro Tajima3, Tomonobu Hasegawa4, Tomohiro Morio1, Kenichi Kashimada1.   

Abstract

BACKGROUND: One of the major purposes of newborn screening for 21-hydroxylase deficiency (21OHD) is preventing life-threatening adrenal crisis. However, the details of adrenal crisis in newborns are not precisely documented. AIM: We aimed to clarify the clinical details of salt-wasting in newborn 21OHD patients.
METHODS: Based on the follow-up survey of the screening in Tokyo from 1989 to 2017, we retrospectively analysed the conditions of classical 21OHD neonates before the initiation of therapy.
RESULTS: One hundred classical 21OHD patients (55 male, 45 female) were analysed. The age at the first hospital visit was 0-20 days with sex difference (male: 9.0 ± 3.5 days; female: 6.2 ± 3.9 days). Thirty-seven (37.4%) patients exhibited severe salt-wasting (SSW), that is, Na < 130 mEq/L, K > 7 mEq/L or Na/K ratio < 20; except for one case, SSW developed in or after the second week of life. The serum concentrations of Na, K and Na/K were linearly correlated with age in days (R2  = .38, .25, and .34 respectively), suggesting that the risk of SSW increases linearly without a threshold. The age at which the regression lines reached Na < 130 mEq/L, K > 7 mEq/L and Na/K < 20 was approximately coincided, 11.1, 12.3 and 11.2 days, respectively. All SSW patients exhibited decreased body weight from birth in their second week of life.
CONCLUSION: Our data revealed that the risk of developing SSW increases during the second week of life without a threshold, and for preventing SSW, early intervention, ideally during first week of life, is desirable. An increased body weight in the second week of life indicates the absence of SSW.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  congenital adrenal hyperplasia; hyperkalaemia; hyponatremia; newborn screening; salt-wasting crisis

Year:  2020        PMID: 33001476     DOI: 10.1111/cen.14347

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  3 in total

1.  Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision).

Authors:  Tomohiro Ishii; Kenichi Kashimada; Naoko Amano; Kei Takasawa; Akari Nakamura-Utsunomiya; Shuichi Yatsuga; Tokuo Mukai; Shinobu Ida; Mitsuhisa Isobe; Masaru Fukushi; Hiroyuki Satoh; Kaoru Yoshino; Michio Otsuki; Takuyuki Katabami; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2022-04-10

2.  [Newborn screening for congenital hypothyroidism and congenital adrenal hyperplasia: Benefits and costs of a successful public health program].

Authors:  Guy Van Vliet; Scott D Grosse
Journal:  Med Sci (Paris)       Date:  2021-05-18       Impact factor: 0.716

3.  High-dose fludrocortisone therapy was transiently required in a female neonate with 21-hydroxylase deficiency.

Authors:  Yusuke Kawasaki; Takeshi Sato; Satsuki Nakano; Takeshi Usui; Satoshi Narumi; Tomohiro Ishii; Tomonobu Hasegawa
Journal:  Clin Pediatr Endocrinol       Date:  2022-03-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.